Figure 3 | Signal Transduction and Targeted Therapy

Figure 3

From: Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Figure 3

Characteristics and influential factors of expansion of the Chimeric Antigen Receptor-modified T-20 (CART-20) cells in vivo. (a) The time course shows that the peak levels of the CART-20 cells detected by qRT-PCR were observed at approximately 4 weeks after infusion and gradually decreased thereafter. (b) Detection of CART-20 cells at 1 week and 4 weeks after infusion was independent of the infused T-cell dose. (c) A copy number less than 200 (no./mg gDNA) was regarded as CART-20 cell negative. The last observance of positive CART-20 cells was independent of the absolute effects of memory and central memory T cells.

Back to article page